a级黄色片免费播放_亚洲色最新高清av网站_午夜天堂AV免费在线观看_五月天婷亚洲天综合网手机

159-2642-3062 027-65317797
服務(wù)熱線（工作日：9:00-17:30）

瀏覽量: 148

  • 產(chǎn)品名稱： MMAF
  • 產(chǎn)品貨號(hào)： CS00039
  • 貨期： 現(xiàn)貨
  • 價(jià)格與訂購： 450
  • 數(shù)量：
    庫存： 10
  • 規(guī)格： 10mg
  • 產(chǎn)品信息
  • 如何訂購
    產(chǎn)品描述
    Monomethyl auristatin F, an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin. 
    靶點(diǎn)活性
    Cytotoxicity( Karpas 299 cell) 
    體外活性
    MMAF shows in vitro cytotoxicity against a panel of cell lines. The IC50 values for Karpas 299, H3396, 786-O and Caki-1 are 119, 105, 257, and 200 nM, respectively. Targeted MMAF is much more potent than the free drug, and that cAC10 conjugates of MMAF display pronounced activities. On a molar basis, the cAC10-L1-MMAF4 is an average of over 2200-fold more potent than free MMAF and is active on all the CD30-positive cell lines tested[1]. 
    體內(nèi)活性
    The maximum tolerated dose in mice of MMAF (>16 mg/kg) is much higher than MMAE (1 mg/kg). cAC10-L1-MMAF4 has an MTD of 50 mg/kg in mice and 15 mg/kg in rats. The corresponding cAC10-L4-MMAF4 ADC was much less toxic, having MTDs in mice and rats of >150 mg/ kg and 90 mg/kg in rats, respectively[1].
    細(xì)胞實(shí)驗(yàn)
    Cells are treated with serial dilutions of test molecules and incubated 4-6 days depending on cell line. Assessment of cellular growth and data reduction to generate IC50 values is done using Alamar Blue dye reduction assay[2]. 
    別名
    一甲基澳瑞他汀 F , MonoMethyl auristatin F , 
    純度
    98%
    分子量
    731.98
    分子式
    C39H65N5O8
    CAS No.
    745017-94-1 
    存儲(chǔ)
    Powder: -20°C for 3 years
    In solvent: -80°C for 2 years
    溶解度
    DMSO: Soluble
    ( < 1 mg/ml refers to the product slightly soluble or insoluble )
    參考文獻(xiàn)
    1. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
    2. Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
    Note
    For research use only .